vs
CareDx, Inc.（CDNA）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的3.3倍（$117.7M vs $35.5M），CareDx, Inc.净利率更高（2.4% vs -304.2%，领先306.6%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 39.0%），CareDx, Inc.自由现金流更多（$514.0K vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 12.9%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CDNA vs RXRX — 直观对比
营收规模更大
CDNA
是对方的3.3倍
$35.5M
营收增速更快
RXRX
高出642.8%
39.0%
净利率更高
CDNA
高出306.6%
-304.2%
自由现金流更多
CDNA
多$47.8M
$-47.3M
两年增速更快
RXRX
近两年复合增速
12.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $35.5M |
| 净利润 | $2.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 2.4% | -304.2% |
| 营收同比 | 39.0% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $0.05 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARXRX
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $35.5M | ||
| Q3 25 | $100.1M | $5.2M | ||
| Q2 25 | $86.7M | $19.2M | ||
| Q1 25 | $84.7M | $14.7M | ||
| Q4 24 | $86.6M | $4.5M | ||
| Q3 24 | $82.9M | $26.1M | ||
| Q2 24 | $92.3M | $14.4M |
净利润CDNARXRX
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-108.1M | ||
| Q3 25 | $1.7M | $-162.3M | ||
| Q2 25 | $-8.6M | $-171.9M | ||
| Q1 25 | $-10.4M | $-202.5M | ||
| Q4 24 | $87.7M | $-178.9M | ||
| Q3 24 | $-10.6M | $-95.8M | ||
| Q2 24 | $-4.6M | $-97.5M |
毛利率CDNARXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率CDNARXRX
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | -304.8% | ||
| Q3 25 | -0.2% | -3327.6% | ||
| Q2 25 | -12.8% | -916.8% | ||
| Q1 25 | -15.8% | -1297.9% | ||
| Q4 24 | 97.5% | -4042.4% | ||
| Q3 24 | -16.6% | -377.1% | ||
| Q2 24 | -7.9% | -697.4% |
净利率CDNARXRX
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -304.2% | ||
| Q3 25 | 1.7% | -3135.3% | ||
| Q2 25 | -9.9% | -894.2% | ||
| Q1 25 | -12.2% | -1373.3% | ||
| Q4 24 | 101.3% | -3935.5% | ||
| Q3 24 | -12.8% | -367.5% | ||
| Q2 24 | -5.0% | -676.6% |
每股收益（稀释后）CDNARXRX
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $-0.17 | ||
| Q3 25 | $0.03 | $-0.36 | ||
| Q2 25 | $-0.16 | $-0.41 | ||
| Q1 25 | $-0.19 | $-0.50 | ||
| Q4 24 | $1.60 | $-0.56 | ||
| Q3 24 | $-0.20 | $-0.34 | ||
| Q2 24 | $-0.09 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | — | $1.1B |
| 总资产 | $411.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CDNARXRX
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $743.3M | ||
| Q3 25 | $194.2M | $659.8M | ||
| Q2 25 | $186.3M | $525.1M | ||
| Q1 25 | $230.9M | $500.5M | ||
| Q4 24 | $260.7M | $594.4M | ||
| Q3 24 | $240.9M | $427.6M | ||
| Q2 24 | $228.9M | $474.3M |
总债务CDNARXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | $0 | $20.5M | ||
| Q2 24 | $0 | $22.9M |
股东权益CDNARXRX
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $1.1B | ||
| Q3 25 | $311.1M | $1.0B | ||
| Q2 25 | $327.4M | $919.1M | ||
| Q1 25 | $379.3M | $933.9M | ||
| Q4 24 | $378.4M | $1.0B | ||
| Q3 24 | $273.2M | $524.6M | ||
| Q2 24 | $264.7M | $584.4M |
总资产CDNARXRX
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.5B | ||
| Q3 25 | $432.3M | $1.4B | ||
| Q2 25 | $444.3M | $1.3B | ||
| Q1 25 | $489.6M | $1.3B | ||
| Q4 24 | $491.1M | $1.4B | ||
| Q3 24 | $477.0M | $726.5M | ||
| Q2 24 | $466.8M | $775.9M |
负债/权益比CDNARXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | 0.00× | 0.04× | ||
| Q2 24 | 0.00× | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $-47.3M |
| 自由现金流率自由现金流/营收 | 0.4% | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CDNARXRX
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $-46.1M | ||
| Q3 25 | $37.4M | $-117.4M | ||
| Q2 25 | $9.9M | $-76.4M | ||
| Q1 25 | $-26.6M | $-132.0M | ||
| Q4 24 | $21.9M | $-115.4M | ||
| Q3 24 | $12.5M | $-59.2M | ||
| Q2 24 | $18.9M | $-82.2M |
自由现金流CDNARXRX
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M |
自由现金流率CDNARXRX
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% |
资本支出强度CDNARXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% |
现金转化率CDNARXRX
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Testing services revenue | $91.4M | 78% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
RXRX
暂无分部数据
